GSK is moving to expand its oncology business by acquiring Nuvalent, a US-listed cancer drug specialist. Multiple reports describe the transaction as one of GSK’s largest deals in about a decade. Bloomberg and The Guardian say GSK has agreed to buy Nuvalent for $10.6 billion, highlighting Nuvalent’s pipeline and its focus on lung cancer treatments, including late-stage medications. MarketWatch similarly frames the purchase as GSK’s biggest acquisition in eight years and connects it to efforts to rebuild a cancer portfolio that GSK previously reduced.
However, earlier reporting cited by Seeking Alpha, CNBC, and Bloomberg notes that GSK was in talks to buy Nuvalent for more than $9 billion, citing the Financial Times and unnamed sources. Belfast Telegraph, The Independent, and The Guardian also provide a UK-sterling valuation for the deal, describing it as about £8 billion.
Overall, the coverage is consistent that GSK is targeting Nuvalent to strengthen oncology offerings, with figures ranging from discussions above $9 billion to a finalized $10.6 billion agreement, depending on the timing of each report.
